RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.
2 reports, 0 independent
Updated Jul 7
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- RBC raised price target on Alnylam Pharmaceuticals.
- RBC raised price target on Acadia Pharmaceuticals.
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
-
Royal Bank of Canada
financial institution in Canada
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
Nothing else this week.
Related events
- Royal Bank of Canada raised its price target on Webster Financial on July 2, 2025.
- Royal Bank of Canada lifted its target price for Aurinia Pharmaceuticals Inc. on October 9, 2026.
- RBC, Keefe, Bruyette & Woods, and Morgan Stanley issued rating and price target updates for D.R. Horton, Inc.
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.
- RBC lifted its price target on Lockheed Martin shares, which also filed holdings with the SEC.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet